NKTX Nkarta Inc

Price (delayed)

$2.49

Market cap

$122.19M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.5

Enterprise value

$170.65M

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off the shelf natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with ...

Highlights

NKTX's EPS is up by 6% year-on-year and by 2.3% since the previous quarter

Nkarta's net income has decreased by 18% YoY but it has increased by 2.2% QoQ

NKTX's quick ratio is down by 27% year-on-year

Nkarta's equity has decreased by 26% YoY and by 7% QoQ

Sector: Healthcare

Industry: Biotechnology

Website: http://www.nkartatx.com

Peers: OMGA

Key stats

What are the main financial stats of NKTX

Market

Shares outstanding

49.07M

Market cap

$122.19M

Enterprise value

$170.65M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

0.41

Price to sales (P/S)

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

Earnings

Revenue

EBIT

-$122.33M

EBITDA

-$115.66M

Free cash flow

-$126.52M

Per share

EPS

-$2.5

Free cash flow per share

-$2.58

Book value per share

$6.05

Revenue per share

TBVPS

$8.27

Balance sheet

Total assets

$405.86M

Total liabilities

$109.05M

Debt

$89.47M

Equity

$296.82M

Working capital

$255.55M

Liquidity

Debt to equity

0.3

Current ratio

10.97

Quick ratio

10.86

Net debt/EBITDA

-0.42

Margins

EBITDA margin

N/A

Gross margin

N/A

Net margin

N/A

Operating margin

N/A

Efficiency

Return on assets

-27.7%

Return on equity

-36.7%

Return on invested capital

-26.4%

Return on capital employed

-32.2%

Return on sales

N/A

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

NKTX stock price

How has the Nkarta stock price performed over time

Intraday

1.22%

1 week

-3.86%

1 month

21.46%

1 year

-69.22%

YTD

-58.43%

QTD

79.14%

Financial performance

How have Nkarta's revenue and profit performed over time

Revenue

Gross profit

Operating income

-$135.45M

Net income

-$122.33M

Gross margin

N/A

Net margin

N/A

Nkarta's operating income has decreased by 27% YoY

Nkarta's net income has decreased by 18% YoY but it has increased by 2.2% QoQ

Growth

What is Nkarta's growth rate over time

Valuation

What is Nkarta stock price valuation

P/E

N/A

P/B

0.41

P/S

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

NKTX's EPS is up by 6% year-on-year and by 2.3% since the previous quarter

Nkarta's equity has decreased by 26% YoY and by 7% QoQ

The P/B is 18% below the last 4 quarters average of 0.5

Efficiency

How efficient is Nkarta business performance

NKTX's return on equity is down by 15% year-on-year and by 5% since the previous quarter

The ROA has contracted by 6% YoY and by 3.4% from the previous quarter

NKTX's return on invested capital is up by 6% year-on-year but it is down by 2.3% since the previous quarter

Dividends

What is NKTX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for NKTX.

Financial health

How did Nkarta financials performed over time

The current ratio has contracted by 28% YoY

NKTX's quick ratio is down by 27% year-on-year

NKTX's debt is 70% smaller than its equity

NKTX's debt to equity is up by 43% year-on-year and by 7% since the previous quarter

Nkarta's equity has decreased by 26% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.